1721 – Small gene panel testing for non-small cell lung carcinoma

Page last updated: 22 June 2022

Application Detail

Description of Medical Service

Next generation sequencing panel testing involves nucleic acid extraction from a tissue biopsy sample, which then undergoes target enrichment treatment. Genomic variants are then curated by scientists/pathologists and a clinical report generated.

Description of Medical Condition

Non-small cell lung cancer (NSCLC) is any type of epithelial lung cancer other than small cell lung cancer. The most common types of NSCLC are squamous cell carcinoma, large cell carcinoma, and adenocarcinoma.Most NSCLC patients have symptoms at the time of diagnosis. Depending on the stage of disease and the type of lung cancer, treatment options may include surgery, radiotherapy, chemotherapy, immunotherapy, or molecularly targeted therapy.

Reason for Application

New MBS item

Medical Service Type

Investigative technology

Previous Application Number/s

Not Applicable

Associated Documentation

Application Form

Application Form (PDF 678 KB)
Application Form (Word 328 KB)

Consultation Survey

Consultation Survey (PDF 316 KB)
Consultation Survey (Word 72 KB)

PASC Consultation
Expedited - Bypassing PASC

MSAC Consultation
MSAC consultation input must be received by no later than Friday, 7 October 2022 for it to be considered by MSAC at its November 2022 meeting.

For further information please refer to PASC, ESC, MSAC Key Dates
For further information on the consultation process please refer to MSAC Consultation Process

PICO Confirmation

-

Assessment Report

-

Public Summary Document

-

Meetings for this Application

PASC

Expedited Bypassing PASC

ESC

6-7 October 2022

MSAC

24-25 November 2022